The slowdown in economic activity and supply chain disruptions gave the unprecedented lockdown to arrest the spread of the Covid-19 pandemic continued to impact the business at the beginning of the first quarter of 2020-21. As the restrictions were subsequently eased, Dabur India quickly scaled up operations to reach near-normal levels in May and June 2020. Dabur India ended Q1 of 2020-21 with a 12.9% drop in consolidated revenue from operations at Rs 1,980 crore against Rs 2,273 crore a year earlier. Consolidated net profit for the quarter stood at Rs 342 crore, down 5.9% from Rs 363 crore a year ago.
Gain in market share in key categories
In the Standalone India Business, Dabur India reported a 12.3% growth in net profit at Rs 289.4 crore in Q1 2020-21, up from Rs 257.8 crore a year earlier. Standalone revenue for the quarter stood at Rs 1,491 crore as against Rs 1,628 crore a year ago. According to reports, Dabur also continued to gain market share across all key categories like Chyawanprash, toothpaste, and packaged juices and nectars, during the quarter.
“We entered this crisis from a position of strength. We were growing at a steady pace when the Covid pandemic brought business to a standstill. Amidst this challenging business environment, we quickly revamped our portfolio to meet the growing consumer need for quality Preventive Healthcare, Personal Hygiene and Household Hygiene products, while enhancing production of our existing Ayurvedic Immunity boosters like Dabur Chyawanprash and Dabur Honey. Despite a challenging April, the quarter saw a nearly 7-fold growth in demand for Dabur Chyawanprash and an over 60% surge in demand for Dabur Honey. Dabur has significantly ramped up capacity with production now at near-normal levels and the business poised to deliver growth for the rest of the year,” Dabur India chief executive officer Mohit Malhotra said.
Dabur Chyawanprash reported a growth of over 694% during the quarter, while Dabur Honitus grew by over 80% while Dabur Honey ended Q1 2020-21 with a growth of over 60%. The quarter saw Dabur introduce a record number of new products and variants anchored on the consumer need for Health, Immunity, and Hygiene. The quarter saw our new products record Sales of over Rs 100 crore.
“We will continue to invest behind our Power Brands, many of which are in the Healthcare space, to drive business growth. Going forward, we will also capitalize on the emerging tailwinds. Our distribution might further strengthen our position as a frontrunner in the Ayurvedic Healthcare and Hygiene products markets,” Malhotra added.
Riding on the strong demand for Dabur Chyawanprash and Dabur Honey, Dabur’s Health Supplements Business reported a 53% growth during Q1 of 2020-21. The OTC Healthcare Business ended the quarter with a 34% growth while the Ayurvedic Ethicals business was up 11%. On the back of continued demand for our flagship Dabur Red Paste, the toothpaste business ended the quarter with a nearly 3% growth. Other categories have also witnessed improvement in sales sequentially through the quarter.
Dabur India is one of India’s leading FMCG companies. Building on a legacy of quality and experience for 136 years, Dabur is today India’s most trusted name and one of the world’s largest ayurvedic and natural healthcare companies. Dabur India’s FMCG portfolio includes eight distinct brands – Dabur Amla, Dabur Chyawanprash, Dabur Honey, Honitus, PudinHara, Dabur Lal Tail, Réal and Vatika.